Matches in SemOpenAlex for { <https://semopenalex.org/work/W3005778076> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W3005778076 endingPage "1883" @default.
- W3005778076 startingPage "1876" @default.
- W3005778076 abstract "This study aimed to analyze prognostic factors for survival and the reliability and the effectiveness of eribulin therapy in metastatic breast cancer (MBC) patients.A total of 80 patients treated with eribulin in 12 medical oncology centers in Turkey between 2013-2017 were retrospectively evaluated. Sixteen potential prognostic variables were assessed for analysis.The patients had received a median of 5 prior chemotherapy regimens and a median of 3 eribulin cycles for MBC. Median progression-free survival (PFS) was 5.5 months (95% Cl: 4.1-7.8) and median overall survival (OS) was 11 months (95 % Cl: 6-15). Multivariate analysis showed that eribulin treatment line was shown to have independent prognostic significance for PFS. PFS difference was demostrated in patients who received 3 chemotherapy lines for advanced disease compared to those who had more than 3 chemotherapy lines [median PFS; 3 lines: 8.6 months (6.2-11) and ˃3 lines: 4.6 months (3.7-4.6) p=0.00]. The clinical benefit rate (CBR) was 52.5 and 35% in patients treated with three lines and with ˃3 previous chemotherapeutic regimens. Most common toxicities were neutropenia (62.5%), fatigue (52.5%), alopecia (50%) and nausea (37.5%).Eribulin treatment line was identified as indepedent prognostic factor for PFS in MBC patients." @default.
- W3005778076 created "2020-02-24" @default.
- W3005778076 creator A5000554665 @default.
- W3005778076 creator A5000962715 @default.
- W3005778076 creator A5003760026 @default.
- W3005778076 creator A5012195445 @default.
- W3005778076 creator A5026108996 @default.
- W3005778076 creator A5030391626 @default.
- W3005778076 creator A5042914606 @default.
- W3005778076 creator A5067494252 @default.
- W3005778076 creator A5067982149 @default.
- W3005778076 creator A5068468956 @default.
- W3005778076 creator A5069536993 @default.
- W3005778076 creator A5070058833 @default.
- W3005778076 creator A5075330567 @default.
- W3005778076 creator A5086747983 @default.
- W3005778076 date "2019-12-02" @default.
- W3005778076 modified "2023-10-16" @default.
- W3005778076 title "Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study." @default.
- W3005778076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32521847" @default.
- W3005778076 hasPublicationYear "2019" @default.
- W3005778076 type Work @default.
- W3005778076 sameAs 3005778076 @default.
- W3005778076 citedByCount "0" @default.
- W3005778076 crossrefType "journal-article" @default.
- W3005778076 hasAuthorship W3005778076A5000554665 @default.
- W3005778076 hasAuthorship W3005778076A5000962715 @default.
- W3005778076 hasAuthorship W3005778076A5003760026 @default.
- W3005778076 hasAuthorship W3005778076A5012195445 @default.
- W3005778076 hasAuthorship W3005778076A5026108996 @default.
- W3005778076 hasAuthorship W3005778076A5030391626 @default.
- W3005778076 hasAuthorship W3005778076A5042914606 @default.
- W3005778076 hasAuthorship W3005778076A5067494252 @default.
- W3005778076 hasAuthorship W3005778076A5067982149 @default.
- W3005778076 hasAuthorship W3005778076A5068468956 @default.
- W3005778076 hasAuthorship W3005778076A5069536993 @default.
- W3005778076 hasAuthorship W3005778076A5070058833 @default.
- W3005778076 hasAuthorship W3005778076A5075330567 @default.
- W3005778076 hasAuthorship W3005778076A5086747983 @default.
- W3005778076 hasConcept C121608353 @default.
- W3005778076 hasConcept C126322002 @default.
- W3005778076 hasConcept C141071460 @default.
- W3005778076 hasConcept C143998085 @default.
- W3005778076 hasConcept C2775930923 @default.
- W3005778076 hasConcept C2776387010 @default.
- W3005778076 hasConcept C2776694085 @default.
- W3005778076 hasConcept C2777063308 @default.
- W3005778076 hasConcept C2780739268 @default.
- W3005778076 hasConcept C530470458 @default.
- W3005778076 hasConcept C71924100 @default.
- W3005778076 hasConceptScore W3005778076C121608353 @default.
- W3005778076 hasConceptScore W3005778076C126322002 @default.
- W3005778076 hasConceptScore W3005778076C141071460 @default.
- W3005778076 hasConceptScore W3005778076C143998085 @default.
- W3005778076 hasConceptScore W3005778076C2775930923 @default.
- W3005778076 hasConceptScore W3005778076C2776387010 @default.
- W3005778076 hasConceptScore W3005778076C2776694085 @default.
- W3005778076 hasConceptScore W3005778076C2777063308 @default.
- W3005778076 hasConceptScore W3005778076C2780739268 @default.
- W3005778076 hasConceptScore W3005778076C530470458 @default.
- W3005778076 hasConceptScore W3005778076C71924100 @default.
- W3005778076 hasIssue "5" @default.
- W3005778076 hasLocation W30057780761 @default.
- W3005778076 hasOpenAccess W3005778076 @default.
- W3005778076 hasPrimaryLocation W30057780761 @default.
- W3005778076 hasRelatedWork W2023654245 @default.
- W3005778076 hasRelatedWork W2092771806 @default.
- W3005778076 hasRelatedWork W2139647583 @default.
- W3005778076 hasRelatedWork W2192078226 @default.
- W3005778076 hasRelatedWork W2571164384 @default.
- W3005778076 hasRelatedWork W2767929921 @default.
- W3005778076 hasRelatedWork W2782589310 @default.
- W3005778076 hasRelatedWork W2794674313 @default.
- W3005778076 hasRelatedWork W3165784947 @default.
- W3005778076 hasRelatedWork W3217783517 @default.
- W3005778076 hasVolume "24" @default.
- W3005778076 isParatext "false" @default.
- W3005778076 isRetracted "false" @default.
- W3005778076 magId "3005778076" @default.
- W3005778076 workType "article" @default.